Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saizen in children born with serious intra-uterine growth retardation treated to final height
2015-001708-69Phase 3
- Sponsor
- Merck KGaA
- Start
- Jul 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of somatropin in intrauterine growth restriction (IUGR) (2 arms), sponsored by Merck KGaA. Primary endpoint: Final Height.
02
Drugs
somatropin
03
Conditions
intrauterine growth restriction (IUGR)
Beyond the preview
Go deeper on 2015-001708-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001708-69.